Authors
Latest:
Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy and Oxaliplatin-Induced Fever Associated With IL-6 Release in a Patient With Locally Advanced Colon CancerThis case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Latest:
Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and FutureMcCall and Higgins examine local ablative therapy for oligometastatic NSCLC and implications for future treatment of the disease.
Latest:
Balancing a Family and an Emerging Career in Public HealthPublic health researchers highlight how they learned to overcome and adapt to disparities observed during their careers.
Latest:
Perspectives on COVID-19 Prophylaxis and VaccinationTo close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).
Latest:
CBM588 May Improve Clinical Outcomes in Metastatic RCCAnalysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Latest:
Understanding Advanced RCC: Epidemiology, Presentation, and Risk StratificationPanelists discuss advanced renal cell carcinoma (RCC), including its epidemiology, typical disease presentation, and the common patient profile in terms of age, gender, and family history, while also addressing the risk stratification for advanced RCC, highlighting the differences between favorable and poor/intermediate risk categories.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Ongoing Consolidative RT Trial May Support Efficacy Findings in SCLCJames Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.
Latest:
Jonathan Spicer, MD, PhD, Discusses Multidisciplinary Communication for Treating Resectable NSCLC With Neoadjuvant ImmunotherapyCancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.
Latest:
Profilin 1 Protein and Its Implications for CancersProfilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.
Latest:
Caring for Patients With Serious Mental Illness: Guide for the Oncology ClinicianVeronica B. Decker, DNP, MBA, APRN, PMHCNS-BC, and colleagues discuss how to care for patients with cancer and serious mental illness.
Latest:
Asciminib Appears to Benefit All Chronic Myeloid Leukemia SubgroupsCompared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Latest:
The Effect of Prior Cancer on Survival of Patients With ThymomaShilong Wu, MD, and co-authors discuss how patients with thymoma are affected by prior cancer history.
Latest:
Relapsed/Refractory HER2+ Metastatic Breast CancerRecommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Frontline Combination Therapy Intensification May Improve Survival in NSCLCHigher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Latest:
Yazeed Sawalha, MD, on Use of Autologous Stem Cell Transplant in Mantle Cell LymphomaYazeed Sawalha, MD, discusses how often autologous stem cell transplant is utilized in patients with mantle cell lymphoma.
